1. Market Research
  2. > All Companies
  3. > Pharmesis International Ltd. (P31) - Financial and Strategic SWOT Analysis Review

Pharmesis International Ltd. (P31) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Pharmesis International Ltd. (Pharmesis) is a pharmaceutical company. The company carries out the research, development production, and commercialization of Western medicine and traditional Chinese Medicine. It provides formulated products such as anetholtrithione (ATT) for the treatment of illnesses relating to the liver and gall bladder. The company provides products such as kinna, longlife and health supplements. Pharmesis products are sold to approximately 2,000 hospitals all over the China. Its production facilities have 41,206 sq m, area and are located in the cities of Chengdu and Guilin in the Sichuan Province. The company’s research and development team collaborates with research institutes in China to identify and develop new pharmaceutical products. Pharmesis is headquartered in Chengdu, Sichuan, China.

Pharmesis International Ltd. Key Recent Developments

May 13, 2013: Pharmesis Reports Revenue Of RMB15.2m In Q1 2013

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Pharmesis International Ltd. (P31) - Financial and Strategic SWOT Analysis Review
Table of Contents

Section 1 - About the Company 6
Pharmesis International Ltd. - Key Facts 6
Pharmesis International Ltd. - Key Employees 7
Pharmesis International Ltd. - Key Employee Biographies 8
Pharmesis International Ltd. - Key Operational Employees 9
Pharmesis International Ltd. - Major Products and Services 10
Pharmesis International Ltd. - History 11
Pharmesis International Ltd. - Company Statement 12
Pharmesis International Ltd. - Locations And Subsidiaries 13
Head Office 13
Other Locations and Subsidiaries 13
Section 2 - Company Analysis 14
Pharmesis International Ltd. - Business Description 14
Pharmesis International Ltd. - SWOT Analysis 15
SWOT Analysis - Overview 15
Pharmesis International Ltd. - Strengths 15
Strength - Broad Product Offerings 15
Strength - Focused RandD Activities 15
Strength - Improved Financial Performance 15
Pharmesis International Ltd. - Weaknesses 16
Weakness - Geographical Concentration: China 16
Pharmesis International Ltd. - Opportunities 16
Opportunity - Growing Aged Population in China 16
Opportunity - Market Potential: HCV 16
Opportunity - Chinese Pharmaceutical Market 16
Pharmesis International Ltd. - Threats 16
Threat - Intense Competition 16
Threat - Stringent Government Regulations 17
Threat - Uncertain RandD Outcomes 17
Pharmesis International Ltd. - Key Competitors 18
Section 3 - Company Financial Ratios 19
Financial Ratios - Capital Market Ratios 19
Financial Ratios - Annual Ratios 20
Performance Chart 21
Financial Performance 21
Financial Ratios - Interim Ratios 22
Financial Ratios - Ratio Charts 23
Section 4 - Company's Recent Developments 24
May 13, 2013: Pharmesis Reports Revenue Of RMB15.2m In Q1 2013 24
Section 5 - Appendix 25
Methodology 25
Ratio Definitions 25
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables

Pharmesis International Ltd., Key Facts 6
Pharmesis International Ltd., Key Employees 7
Pharmesis International Ltd., Key Employee Biographies 8
Pharmesis International Ltd., Key Operational Employees 9
Pharmesis International Ltd., Major Products and Services 10
Pharmesis International Ltd., History 11
Pharmesis International Ltd., Other Locations 13
Pharmesis International Ltd., Subsidiaries 13
Pharmesis International Ltd., Key Competitors 18
Pharmesis International Ltd., Ratios based on current share price 19
Pharmesis International Ltd., Annual Ratios 20
Pharmesis International Ltd., Interim Ratios 22
Currency Codes 25
Capital Market Ratios 25
Equity Ratios 26
Profitability Ratios 26
Cost Ratios 27
Liquidity Ratios 27
Leverage Ratios 28
Efficiency Ratios 28

List of Figures

Pharmesis International Ltd., Performance Chart (2009 - 2013) 21
Pharmesis International Ltd., Ratio Charts 23

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.